What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Ruxolitinib shows moderate clinical benefits over standard treatments, particularly in controlling blood cell counts and reducing spleen size, as evidenced by the phase 3 RESPONSE and RESPONSE-2 trials. However, the uncertainty regarding its impact on overall survival limits the rating to A.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for ruxolitinib are below the £20,000 per QALY threshold, indicating it is a cost-effective option for the Healthcare. The committee noted that the ICERs were acceptable, supporting a strong economic case.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence suggests that ruxolitinib improves quality of life by reducing symptoms such as fatigue and itching, which are significant burdens for patients with polycythaemia vera. However, the exact impact on HRQoL measures remains uncertain due to the use of different utility measures.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Ruxolitinib has an acceptable safety profile with manageable adverse effects. While there are potential risks, such as infections and weight gain, these can be mitigated, leading to an overall good safety rating.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was compared against best available therapy, which includes hydroxycarbamide and interferon alfa, both of which are relevant and commonly used in clinical practice for polycythaemia vera.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a representative patient population with relevant subgroups, particularly those intolerant to hydroxycarbamide. However, there are some limitations in generalizability due to the specific inclusion criteria.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Ruxolitinib can be integrated into existing treatment pathways with minor adjustments, as it is intended for patients who cannot tolerate or are resistant to hydroxycarbamide.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of ruxolitinib are manageable, and the treatment is expected to provide net savings in the context of the Healthcare, aligning with budgetary considerations.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by multiple phase 3 trials, although there are some limitations regarding the generalizability of the results and the indirect treatment comparisons used.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is notable uncertainty regarding the long-term survival benefits of ruxolitinib, which affects the overall confidence in the treatment’s impact. This uncertainty is acknowledged in the committee’s discussions.
